Epalrica-M Tablet SR is a sustained-release formulation combining Epalrestat 150 mg and Methylcobalamin 1500 mcg, designed for the management of diabetic neuropathy. Epalrestat, an aldose reductase inhibitor, acts by preventing the accumulation of sorbitol in nerve tissues, thereby reducing osmotic and oxidative stress associated with hyperglycemia-induced nerve damage. This mechanism helps in alleviating symptoms such as numbness, tingling, and burning sensations commonly experienced in diabetic peripheral neuropathy. Methylcobalamin, an active form of vitamin B12, supports nerve regeneration and repair by promoting myelin sheath synthesis and enhancing neuronal metabolism. The sustained-release property of the tablet ensures prolonged therapeutic plasma concentrations, improving patient compliance and efficacy. Epalrica-M is indicated for patients with diabetic neuropathy to improve nerve function and reduce neuropathic pain. It should be administered under medical supervision, with dosage adjustments based on clinical response and tolerability. Common adverse effects are generally mild and may include gastrointestinal discomfort or allergic reactions. Caution is advised in patients with renal impairment or hypersensitivity to any component. Regular monitoring of blood glucose and neurological status is recommended during therapy to optimize outcomes and minimize potential risks.